Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocardial Reserve in Advanced Heart Failure Patients
NCT05700617Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milrinone in heart failure (HF) and cardiogenic shock (2 arms), sponsored by University of Chicago. Primary endpoints: Changes in invasive hemodynamics using a pulmonary artery (PA) catheter measuring mmHg at 72 hours, Changes in invasive hemodynamics using a pulmonary artery (PA) catheter measuring L/min/m2 at 72 hours and 5 more. Started Jul 2023; status: recruiting.
02
Drugs
milrinone
03
Conditions
heart failure (HF)cardiogenic shock
Beyond the preview
Go deeper on NCT05700617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700617.